红日药业(300026) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 1,732,429,393.62, representing a 5.70% increase compared to CNY 1,638,989,465.00 in the same period last year[3] - Net profit attributable to shareholders was CNY 238,237,011.30, up 23.34% from CNY 193,160,182.56 year-on-year[3] - Basic earnings per share increased by 33.33% to CNY 0.08 from CNY 0.06 in the same quarter last year[3] - Net profit for the quarter reached CNY 239,797,479.73, compared to CNY 190,354,392.50 in the same period last year, reflecting a growth of approximately 26%[28] - The total comprehensive income attributable to the parent company was CNY 237,091,893.50, compared to CNY 193,747,016.67 in the previous period, representing an increase of approximately 22.4%[31] Cash Flow - The net cash flow from operating activities reached CNY 176,142,534.52, reflecting a 17.91% increase from CNY 149,389,822.89 in the previous year[3] - Cash inflow from operating activities totaled CNY 2,003,293,616.45, up from CNY 1,780,137,951.91, indicating an increase of about 12.5%[32] - The total cash outflow from operating activities was CNY 1,827,151,081.93, compared to CNY 1,630,748,129.02 in the previous period, indicating an increase of approximately 12.0%[35] - The net cash flow from investment activities was CNY -173,811,000.00, a decrease of 70.17% compared to the previous year, attributed to increased capital expenditures[6] - The net cash flow from financing activities was CNY -106,793,165.04, a decline from CNY 11,105,745.81 in the previous period[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,756,400,108.61, a 1.28% increase from CNY 11,607,300,738.29 at the end of the previous year[3] - The company's total liabilities decreased to CNY 3,565,368,085.82 from CNY 3,654,921,077.43, a reduction of about 2.4%[24] - The company's equity attributable to shareholders rose by 3.05% to CNY 8,009,980,558.39 from CNY 7,772,888,664.89 at the end of last year[3] - Total current assets reached ¥6,973,463,669.56, compared to ¥6,806,263,318.08 at the beginning of the year[18] - Non-current assets total ¥4,782,936,439.05, down from ¥4,801,037,420.21[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 201,710[10] - Chengdu Xingcheng Investment Group Co., Ltd. holds 22.24% of shares, totaling 667,997,417 shares[10] - The number of restricted shares held by major shareholders decreased, with Yao Xiaoqing holding 294,196,979 shares after a release of 14,664,750 shares[14] Expenses - Total operating costs amounted to CNY 1,494,467,728.84, up from CNY 1,413,767,708.74, indicating an increase of about 5.7%[24] - Research and development expenses for the quarter were CNY 51,569,849.88, up from CNY 41,084,903.84, indicating an increase of about 25.5%[24] - The company reported a tax expense of CNY 44,364,341.86, compared to CNY 39,271,528.49 in the previous period, which is an increase of approximately 13.5%[28] - Financial expenses increased by 38.65% to CNY 18,212,800.00, mainly due to higher interest expenses[6] Other Income and Gains - Non-recurring gains and losses totaled CNY 35,192,383.61 for the period, primarily due to government subsidies received[5] - The company reported a significant increase in other income, which rose by 233.82% to CNY 20,770,500.00, mainly from government subsidies[6] Market Strategy - The company has no new strategies or significant market expansions reported in the current quarter[13] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]